[Poor management of diarrhea in children in France]

B Topuz1

  • 1btopuz@cg93.fr

Sante Publique (Vandoeuvre-Les-Nancy, France)
|June 10, 2004
PubMed

Insights

Infant diarrhea in France causes thousands of hospitalizations and hundreds of deaths annually. Implementing World Health Organization-recommended oral rehydration therapy can prevent many of these severe outcomes.

Area of Science:

  • Pediatric Gastroenterology
  • Public Health Policy

Context:

  • Infant diarrhea in France leads to significant mortality and morbidity in children under five.
  • Dehydration is the primary cause of hospitalization and death, with preventable cases occurring annually.

Purpose:

  • To highlight the underutilization of World Health Organization (WHO)-recommended oral rehydration salts (ORS) in France.
  • To analyze the systemic failures within the French healthcare system contributing to this practice gap.

Summary:

  • Despite WHO recommendations for oral rehydration therapy (ORT) for infant diarrhea, French physicians often prescribe ineffective antidiarrheal drugs.
  • This failure to adopt evidence-based practices results in preventable deaths and hospitalizations due to dehydration.

Impact:

  • Addressing this practice gap could significantly reduce infant mortality and hospitalizations in France.
  • Systemic changes are needed, including improved epidemiological surveillance, targeted health initiatives, enhanced medical education, and clearer state-pharmaceutical industry relations.

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Cholera01:25

Cholera

Cholera is an acute gastrointestinal disease caused by the Gram-negative bacterium Vibrio cholerae. It is transmitted primarily via the fecal-oral route through the ingestion of contaminated water or food.Vibrio cholerae is a motile, Gram-negative bacterium of the family Vibrionaceae, primarily associated with waterborne outbreaks in areas with inadequate sanitation. Although over 200 serogroups of V. cholerae exist, only O1 and O139 are responsible for epidemic cholera. The O1 serogroup,...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD: